Hypoglycemia

Deep dive

Hypoglycemia: complete reference

Hypoglycemia is abnormally low blood glucose, typically defined as <70 mg/dL (3.9 mmol/L). Symptoms range from mild (hunger, sweating, shakiness, irritability) to severe (confusion, loss of consciousness, seizure). GLP-1 receptor agonists carry low intrinsic hypoglycemia risk when used as monotherapy because their insulin-secretion effect is glucose-dependent (only triggers when glucose is elevated, unlike sulfonylureas or insulin which release insulin regardless). However, when GLP-1s are combined с insulin or sulfonylureas, hypoglycemia risk increases substantially — these older agents already cause hypoglycemia, and adding GLP-1's effects can compound the risk. Patients on combination therapy typically need insulin or sulfonylurea dose reduction when starting a GLP-1. Hypoglycemia management: 15-20g fast-acting carbohydrate (juice, glucose tablets), recheck blood glucose in 15 minutes, repeat if still <70. For severe hypoglycemia (unable to self-treat), glucagon injection or 911 call indicated.

In practice

If you take insulin для diabetes + start Ozempic, expect your prescriber to reduce your insulin dose by 20-50% — adding the GLP-1 effect to existing insulin would cause too-low blood sugar.

Clinical context

GLP-1 monotherapy = low hypoglycemia risk. Combined with insulin/sulfonylurea = high risk requiring dose adjustment.